nature portfolio

Corresponding author(s):	Zeynep H. Gümüş
Last updated by author(s):	Nov 21, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

_					
S	12	Ť١	ıct	ы	CS
ر ا	Lа	u	ادا	LI	CO

n/a	a Confirmed						
	The exact	fact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement					
\boxtimes	A stateme	nent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly					
	The statis Only comm	tatistical test(s) used AND whether they are one- or two-sided common tests should be described solely by name; describe more complex techniques in the Methods section.					
	A descrip	A description of all covariates tested					
	A descrip	scription of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons					
	A full deso	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>						
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings						
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes						
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated						
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.							
Software and code							
Policy information about <u>availability of computer code</u>							
Da	ata collection	No software was used					
Da	ata analysis	Picard (1.07), KING software (1.4), EIGENSOFT (5.0.1), Annovar (2018Apr16)					
For m	or manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and						

Data

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The results here are in part based upon data generated by the TCGA Research Network (https://www.cancer.gov/tcga) and datasets from dbGaP (http://www.ncbi.nlm.nih.gov/gap) through dbGaP accession numbers phs000209, phs000276, phs000296, phs000298, phs000424, phs000654, phs000687, phs000866, phs000876, phs000971, phs001000, phs001101.

arch parti	cipants				
about <u>studies i</u>	nvolving human research participants and Sex and Gender in Research.				
and gender	We performed gender-based analyses (based on self-reported gender information).				
cteristics	The population characteristics such gender, age and smoking history are available.				
	Not applicable				
	applicable				
ation on the appr	oval of the study protocol must also be provided in the manuscript.				
ecific re	porting				
ne below that i	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
E	ehavioural & social sciences				
he document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				
Life sciences study design					
close on these	points even when the disclosure is negative.				
The sample size	e was based on the number of individuals in the underlying cohort studies.				
	We included only samples for which over 75% of the exome was callable and there was no evidence of contamination. We also removed samples with 15% or more missing genotype data.				
In this study, th	re results identified in the discovery cohort were replicated in an independent validation cohort.				
No randomization was used in this case-control study. We used the number of genes with rare synonymous variants as a covariate for each individual to adjust for background variation. Additionally, we used the first two principal components covariates in the discovery cohort to adjust for population difference. We also included gender as a covariate when applicable.					
The investigators were not blinded in the data analysis. The analysis was carried out in case-control setting, so the cases and controls were identified in the beginning of the analysis.					
on from authors sed is relevant to perimental sees study cell lines	n/a Involved in the study ChIP-seq Flow cytometry				
	and gender cteristics cterist				

Palaeontology and archaeology Animals and other organisms

Clinical data

Dual use research of concern